Attributes | Values |
---|
rdf:type
| |
http://linked.open...gbank/description
| - Humanized IgG4k monoclonal antibody produced in murine myeloma cells. Natalizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to a4-integrin. Natalizumab was voluntarily withdrawn from U.S. market because of risk of Progressive multifocal leukoencephalopathy (PML). It was returned to market July, 2006. (en)
|
http://linked.open...y/drugbank/dosage
| |
http://linked.open...generalReferences
| - # Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnalek P, Zadorova Z, Palmer T, Donoghue S: Natalizumab for active Crohn's disease. N Engl J Med. 2003 Jan 2;348(1):24-32. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12510039 # Patent Information "Link":http://www.patentstorm.us/patents/5840299/fulltext.html (en)
|
http://linked.open...gy/drugbank/group
| - approved (en)
- investigational (en)
|
http://linked.open...drugbank/halfLife
| |
http://linked.open...ugbank/indication
| - For treatment of multiple sclerosis. (en)
|
sameAs
| |
Title
| |
adms:identifier
| |
http://linked.open...mechanismOfAction
| - Binds to the α4-subunit of α4b 1 and α4b 7 integrins expressed on the surface of all leukocytes except neutrophils, and inhibits the α4-mediated adhesion of leukocytes to their counter-receptor(s). (en)
|
http://linked.open...drugbank/packager
| |
http://linked.open.../drugbank/synonym
| - Anti-VLA4 (en)
- Anti-alpha4 integrin (en)
|
http://linked.open...umeOfDistribution
| - * 5.7 ± 1.9 L [Multiple Sclerosis (MS) Patients] * 5.2 ± 2.8 L [Crohn's Disease (CD) Patients] (en)
|
http://linked.open.../drug/hasAHFSCode
| |
foaf:page
| |
http://linked.open...l/drug/hasATCCode
| |
http://linked.open.../affectedOrganism
| - Humans and other mammals (en)
|
http://linked.open...casRegistryNumber
| |
http://linked.open...drugbank/category
| |
http://linked.open...rugbank/clearance
| - * 16 +/- 5 mL/hour [patients with MS who did not have PML receiving the repeat IV administration of a 300 mg dose] * 22 +/- 22 mL/hour [Patients with Crohn's Disease receiving the repeat IV administration of a 300 mg dose] (en)
|
http://linked.open...gbank/containedIn
| |
http://linked.open...ank/Melting-Point
| |